Dr. Kahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Gustave L Levy Pl
# 1514
New York, NY 10029Phone+1 212-659-8760Fax+1 212-659-8838
Summary
- Following medical school, I served in the Royal Army of the Netherlands as a first lieutenant, then trained as a psychiatrist in Utrecht and as a neurologist in Amsterdam. I subsequently moved to New York City for a research fellowship in biological psychiatry at Albert Einstein College of Medicine, completed my psychiatry residency at Mount Sinai Hospital, and worked as chief of the psychiatry research unit at the Bronx VA. I moved back to Utrecht in 1993 to be chair of psychiatry at the University Medical Center, and took over leadership of the Brain Center Rudolf Magnus—a hub of research in basic neuroscience, psychiatry, and neurology. In 2017, I returned to Manhattan for my current position, chair of the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
My expertise is in the neurobiology of schizophrenia and other psychotic disorders. One of my most important contributions to the field was helping to establish proof that schizophrenia debuts with cognitive dysfunction, preceding the onset of the first incidence of psychosis by more than a decade. My group also showed that brain volume is one of the most heritable characteristics, paving the way to link brain volumes in health and disease to genetic variation.
My research has been supported by multiple international grants, and I have served on neuroscience grant review boards in the Netherlands, the United Kingdom, and Germany. I have authored or co-authored more than 900 papers, served on the boards of several international research societies, and received several honors including knighthood in the Netherlands; a honorary doctorate at Semmelweis University in Budapest, Hungary; a Fulbright scholarship and the ECNP’s Neuropsychopharmacology Award.
Education & Training
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 1988 - 1992
- University of Groningen Faculty of Medical ScienceClass of 1979
Certifications & Licensure
- NY State Medical License 1993 - 2026
- CT State Medical License 1992 - 2024
Clinical Trials
- Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment Start of enrollment: 2001 Dec 01
- Genetics and Psychopathology in the 22q11 Deletion Syndrome Start of enrollment: 2002 Oct 01
- Optimization of Treatment and Management of Schizophrenia in Europe Start of enrollment: 2011 May 01
- Join now to see all
Publications & Presentations
PubMed
- 89 citationsGenetic Schizophrenia Risk Variants Jointly Modulate Total Brain and White Matter VolumeAfke F. Terwisscha van Scheltinga, Steven C. Bakker, Neeltje E.M. van Haren, Eske M. Derks, Jacobine E. Buizer-Voskamp
Biological Psychiatry. 2013-03-15 - 290 citationsChanges in Cortical Thickness During the Course of Illness in SchizophreniaNeeltje E.M. van Haren, Hugo G. Schnack, Wiepke Cahn, Martijn P. van den Heuvel, Claude Lepage
Archives of General Psychiatry. 2011-09-05 - 16 citationsComparing language lateralization in psychotic mania and psychotic depression to schizophrenia; a functional MRI study.Iris E. C. Sommer, A.J. vd Veer, Jaap Wijkstra, Marco P. Boks, René S. Kahn
Schizophrenia Research. 2007-01-01
Press Mentions
- Mount Sinai Health System and IBM Research Launch Effort That Leverages Artificial Intelligence and Behavioral Data to Improve Mental Health Care for Young PeopleSeptember 12th, 2024
- Accelerating Science to Advance Early Interventions for SchizophreniaOctober 30th, 2020
- Switching Anti-Psychotic Medications Doesn't Improve Outcomes in First Episode Schizophrenia PatientAugust 14th, 2018
- Join now to see all
Grant Support
- Omega fatty aids Trial in Ultra High Risk subjects (PURPOSE)Stanley Foundation2015–2020
- Innovative Medicine InitiativePRISM2016–2019
- European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)EGRIS (European Group Research in schizophrenia)2014–2019
- Genomic studies of bipolar disorder in a large Cohort from The NetherlandsNIH/NIMH2010–2015
- High-density Genome-wide Association Study inSchizophreniaNIMH2006–2010
Committees
- Membership Committee, American College of Neuropsychopharmacology 2016 - 2019
- Scientific Advisory Board, MRC Center for Neuropsychiatric Genetics and Genomics, Cardiff, Wales, UK 2015 - 2017
- President, Schizophrenia International Research Society (SIRS) 2014 - 2016
- Member, NEURON (Network of European Funding for Neuroscience Research) 2010 - 2017
Other Languages
- Dutch, German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: